Navigation Links
ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
Date:10/25/2008

- Results of two Phase III studies affirmed the clinical benefits of ACTEMRA -

NUTLEY, N.J., Oct. 25 /PRNewswire/ -- Data from two Phase III studies showed that patients who suffer from the debilitating and painful effects of rheumatoid arthritis (RA) achieved significant improvements in signs and symptoms when treated with ACTEMRA(R) (tocilizumab) alone or in combination with methotrexate compared with methotrexate alone. The final results of both studies will be presented as oral presentations, along with 13 other abstracts which evaluate ACTEMRA in patients with moderately to severely active RA, at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco, October 24-29.

Results of the RADIATE study, which evaluated difficult-to-treat patients who failed to respond to prior anti-tumor necrosis factor (TNF)-alpha therapies, demonstrated that half of patients treated with ACTEMRA (8 mg/kg) in combination with methotrexate achieved a 20 percent reduction (ACR20)(1) in RA signs and symptoms, compared with 10 percent of patients treated with methotrexate alone.

"Despite treatment with existing therapies, many patients with RA continue to experience symptoms of joint pain and stiffness," said Mark Genovese, M.D., Professor of Medicine at Stanford University School of Medicine. "The compelling results of these studies further support the efficacy and safety of ACTEMRA as a potential new treatment option for managing the chronic signs and symptoms of this debilitating disease."

The AMBITION study, which examined the effects of ACTEMRA (8 mg/kg) as monotherapy, showed that 70 percent of patients receiving ACTEMRA achieved a 20 percent improvement in their signs and symptoms (ACR20), compared with 53 percent of patients receiving methotrexate alone. The study not only successfully met its primary endpoint of non-inferiority in patients with moderate to severe RA, but also demonstrated superiority over the stand
'/>"/>

SOURCE Hoffmann-La Roche Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
2. New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
3. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
4. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
5. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
6. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
7. Successful Results for Mymetics Corporations Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations
8. Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
9. Hibernation-On-Demand Drug Hydrogen Sulfide Significantly Improves Survival After Extreme Blood Loss
10. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
11. New Study: Pine Bark Significantly Reduces Menstrual Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... JORDAN, Utah , July 10, 2014  BC ... solutions, and MiE America , Inc., a leading ... have entered into a long-term agreement naming BC Technical ... the US. MiE and BC Technical ... strategic agreement to establish BC Technical as the service ...
(Date:7/10/2014)... 10, 2014   LabStyle Innovations Corp . ... announced the appointment of Professor Richard B. ... Board of Directors. Prof. Stone brings ... to LabStyle as an entrepreneur, venture capitalist public, ... governance expert. He currently serves on the board ...
(Date:1/15/2014)... 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) ... support, China,s orthopedic instrument industry ... market size rising from 3.28 billion yuan in 2006 ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3
... Sept. 7 According to Millennium Research Group (MRG), ... in Japan,s Ministry of Health Labour and Welfare (MHLW) ... catheters, will lead to double-digit growth in this segment ... market revenues. Unlike in the US ...
... Reportlinker.com announces that a new market research ... Drug Delivery in Central Nervous System Diseases ... http://www.reportlinker.com/p0203542/Drug-Delivery-in-Central-Nervous-System-Diseases---technologiesmarkets-and-companies.html SummaryThe delivery ... a challenge in the treatment of neurological disorders. ...
Cached Medicine Technology:Will MHLW Changes in Reimbursement Drive Japanese Physicians to Increase Usage of Chronic Dialysis Catheters? 2Will MHLW Changes in Reimbursement Drive Japanese Physicians to Increase Usage of Chronic Dialysis Catheters? 3Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 2Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 3Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 4Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 5Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 6Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 7Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 8Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 9Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 10Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 11Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 12Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 13Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 14Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 15Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 16Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies 17
(Date:7/12/2014)... July 12, 2014 Tylenol lawsuits ... to move forward in the federal multidistrict litigation ... Pennsylvania, Bernstein Liebhard LLP reports. According to a ... Lawrence F. Stengel has ordered the deposition of ... Stengel found that the witness’s testimony concerning the ...
(Date:7/12/2014)... "The second toes cross over the big ... wear shoes," said an inventor from East Hartford, Conn. This ... from happening. , He then created a prototype of the ... second and big toes from overlapping. This avoids discomfort and ... and easy to use, it's ideal for people with foot ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 As DePuy ... forward in U.S. courts, Bernstein Liebhard LLP notes the ... ion levels to the failure of metal-on-metal hip replacements. ... of The Journal of Bone & Joint Surgery, looked ... Articular Surface Replacement prostheses at least twelve months earlier. ...
(Date:7/12/2014)... July 12, 2014 “Critical Care ... New and Late-Stage Four-Factor PCCs and Recombinant Products ... the critical care market in the US, UK, ... report provides an estimation of market size for ... covers critical care indications that are being treated ...
(Date:7/12/2014)... Emirates (PRWEB) July 12, 2014 Dubai ... Angeles basketball legend is heading to the UAE. ... six-time champion will be in the UAE from 28-31 ... Weekend in support of diabetes awareness. The event is ... entertainment marketing and event management company based in Dubai. ...
Breaking Medicine News(10 mins):Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3
... is deeply disturbed that the Food and Drug ... vulnerable populations such as women of child-bearing age, ... recommendation flies in the face of decades of ... of mercury from food, especially on the developing ...
... Univita Health will provide an integrated approach to home-based care and ... 15 The launch of a new company aimed at promoting ... Univita Health is introducing new programs and innovating existing services to ... , "Due to falling birthrates and increased ...
... per cent of the men who took part in the ... trial were diagnosed with the disease and the majority of ... published in the December issue of the urology journal ... women aged from 55 to 74 took part in the ...
... Dec. 15 Today, a parent of a mercury-poisoning victim joined ... proposal to stop warning pregnant women and children about exposure risks ... "We,ve known for years that mercury is toxic to ... individual,s status. For FDA to suddenly change the equation to ...
... hair loss for,both men and women is a very traumatic ... help our clients that worked unlike many potions,lotions and product ... it is the only true hair regeneration laser on the ... Medical, Northwestern,University , Mass General, etc.). They are ...
... 15 Greenway Medical Technologies,Inc. today announced that ... (EHR) solution, PrimeSuite(R), won,three "Best in KLAS" awards ... KLAS Awards,report. For the third consecutive year, ... ambulatory EMR category for practices having between six ...
Cached Medicine News:Health News:CU Statement on FDA Position on Mercury From Fish Consumption 2Health News:Launch of New 'Independent Aging' Company Will Address the Needs of the Growing Senior Population 2Health News:Launch of New 'Independent Aging' Company Will Address the Needs of the Growing Senior Population 3Health News:USA's largest ever prostate cancer screening program shows high compliance and consistent results 2Health News:USA's largest ever prostate cancer screening program shows high compliance and consistent results 3Health News:FDA's Proposed Mercury Fish Advice Based on Flawed Science, Say MD and Anti-Mercury Advocates 2Health News:Greenway Medical Technologies' EHR Solution, PrimeSuite, Wins Three 'Best in KLAS' Awards 2Health News:Greenway Medical Technologies' EHR Solution, PrimeSuite, Wins Three 'Best in KLAS' Awards 3Health News:Greenway Medical Technologies' EHR Solution, PrimeSuite, Wins Three 'Best in KLAS' Awards 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: